What news, page-16

https://www.********.au/wp-content/common-images/Logo_TMF_dark.svg
The Motley Fool
James Mickleboro | August 7, 2017 | More on: SPL



In afternoon trade the Starpharma Holdings Limited (ASX: SPL) share price has been amongst the biggest movers on the market.

At the time of writing the dendrimer product developer’s shares are up a massive 10.5% to 84 cents.

What happened?

This morning Starpharma announced promising results from its VivaGel BV phase 3 trials.

According to the release, the trials of the gel for the prevention of recurrent bacterial vaginosis (rBV) achieved their primary objective and demonstrated statistically significant superiority compared to a placebo.

In light of this, the company will now submit a marketing application to the FDA for the gel in relation to the treatment of rBV.

As there are currently no approved products for the prevention of rBV, management believes there is a significant unmet medical need.

Which is great news for shareholders because Starpharma’s CEO Jackie Fairley estimates the market to be worth in excess of US$1 billion per annum globally.

Given that Starpharma’s market capitalisation is approximately $310 million, VivaGel BV has the potential to be a game-changer for the company.

Should you invest?

Overall, I believe the potential of VivaGel BV makes the company well worth keeping a close eye on.

But it is early days and the company must now look to gain FDA approval, which can be a lengthy and costly endeavour.

So for now I would suggest investors keep Starpharma on their watchlist and consider gaining exposure to the sector through the likes of CSL Limited (ASX: CSL) or Bionomics Ltd (ASX: BNO) for the time being.

Alternatively, these hot stocks could be even better options for investors right now. I'm tipping them to smash the market in FY 2018.

Top 3 ASX Blue Chips To Buy In 2017

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleborohas no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!


Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.





By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to ourFinancial Services Guide (FSG) for more information.


More From The Motley Fool Australia
Why the Bubs Australia Ltd share price was crushed today
Why I've never owned Commonwealth Bank of Australia shares
3 dirt cheap ASX shares to buy today
Leading brokers name 2 ASX shares to buy today
2 exciting small-cap tech shares to watch
4 shares every investor should own
Leading brokers list 3 ASX shares to buy today
Bring your portfolio to life with these 3 healthcare shares
3 healthcare shares with big growth potential
Why the Nextdc Ltd share price stormed higher today

by Taboola

Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.

FOOLS ON FACEBOOK
STAY CONNECTED WITH THE FOOL

How 1 Man Turned $10,000 into $8 Million[/paste:font]

• Home
  
• Compare Services
  
• Share Advisor
  
• Dividend Investor
  
• Extreme Opportunities
  
• Hidden Gems
  
• Million Dollar Portfolio
  
• Pro
  
• Everlasting Income
  
• Lakehouse Capital

© 2009 - 2017 The Motley Fool Australia Pty Ltd. All rights reserved.

Financial Services Guide | Privacy Policy |Terms of Service | Subscription Terms of Service

ACN: 146 988 052 | Australian Financial Services Licence (AFSL): 400691

The Motley Fool Australia, PO Box 4635, Ashmore, Qld 4214

localhost 61 queries in 0.297 seconds


Well James you were wrong

• Should you invest?
• Overall, I believe the potential of VivaGel BV makes the company well worth keeping a close eye on.
• But it is early days and the company must now look to gain FDA approval, which can be a lengthy and costly endeavour.
• So for now I would suggest investors keep Starpharma on their watchlist and consider gaining exposure to the sector through the likes of CSL Limited (ASX: CSL) or Bionomics Ltd (ASX: BNO) for the time being.

The share price has appreciated another 25% since tou wrote this article 3 weeks ago